Skip to main content
Clinical Trials/NCT03910296
NCT03910296
Completed
Not Applicable

Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain

Dana-Farber Cancer Institute1 site in 1 country10 target enrollmentFebruary 20, 2019
ConditionsCancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cancer
Sponsor
Dana-Farber Cancer Institute
Enrollment
10
Locations
1
Primary Endpoint
Study feasibility
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this research study is to develop a psychological treatment for patients with cancer, focused on the psychological symptoms they experience during opioid therapy.

Detailed Description

This research study is a treatment development study, which is the first time investigators are developing this psychological intervention in patients with cancer, on opioid therapy. This study is being conducted to develop a psychological intervention designed specifically for individuals with cancer. The purpose of this study is to determine how practical this intervention is, to determine patient satisfaction, and test the study procedures.

Registry
clinicaltrials.gov
Start Date
February 20, 2019
End Date
July 30, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

MiryamYusufov

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

Inclusion Criteria

  • must be at least 18 years of age
  • speak and comprehend English sufficiently to be able to complete the study procedures and participate in psychotherapy in English
  • have been diagnosed with cancer
  • have an estimated survival time ≥6 months (as approximated by palliative care clinic staff)
  • score ≥4 on the Opioid Risk Tool (Webster \& Webster, 2005) with psychosocial distress as one of the positive items.

Exclusion Criteria

  • untreated bipolar disorder
  • untreated psychotic disorders
  • untreated borderline personality disorder
  • have an estimated survival time ≤6 months (as approximated by clinic staff).

Outcomes

Primary Outcomes

Study feasibility

Time Frame: 2 years

Defined by participants' completion of 80% of measures

Secondary Outcomes

  • Intervention acceptability(2 years)

Study Sites (1)

Loading locations...

Similar Trials